Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Regularly reviewing your retirement plan is essential for long-term success. Find out when to make those important assessments.
20,077 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Curious about private access to AI giants? This guide explains how pre-IPO shares anthropic openai work, the real cha...
A midweek surge in Calumet stock followed news of debt reduction, shining a light on how balance-sheet improvements c...
Bitcoin climbs toward $65,000 as inflation data softens. This guide breaks down what the move means for crypto invest...
A practical, easy-to-follow look at ryman hospitality (rhp) earnings. Learn the key metrics, what the latest call sig...
O-I Glass has climbed about 17% over the past year, even as a large fund unloaded roughly $80 million worth of stock....
Prediction market ETFs may grab headlines, but long-term investors should weigh the real costs and risks. This guide ...
Palantir has a large revenue backlog, a major Army contract on the books, and ambitious growth guidance. This analysi...
A CFO sold a sizable block of Perdoceo Education shares during a year of strong stock gains. This guide explains what...
Unlock actionable takeaways from the 2026 earnings call transcript for IFS. This guide translates the quarter’s numbe...
When a prominent fund makes a sizable stake reduction, it often signals more than profit-taking. This article breaks ...
Tech stocks are leading the charge, lifting major indices to new highs. This guide breaks down the drivers, the bigge...